Investor mix
12 investors on record; lead investors include Hillhouse, Yingke Capital.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 4 | 33% |
| Private equity | 4 | 33% |
| Other / undisclosed | 4 | 33% |
Developer of biosimilar monoclonal antibodies for treating multiple diseases
12 investors on record; lead investors include Hillhouse, Yingke Capital.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 4 | 33% |
| Private equity | 4 | 33% |
| Other / undisclosed | 4 | 33% |